A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients with Netherton Syndrome
This research study is for people with Netherton Syndrome and is designed to test a new medicine called DS-2325a. It's a 'Phase 1b/2' study, which means we're looking closely at how safe the medicine is for people, how it moves through the body, and if there are any early hints that it could help improve the condition. Some participants will receive the actual medicine, while others will receive a placebo (a substance that looks like the medicine but has no active ingredients). This helps us understand the medicine's true effects. We'll be carefully checking for any side effects and how people feel during the study, as well as measuring changes in their skin and other symptoms.
En un coup d'œil
De quoi parle cette étude ?
You've found information about a research study looking into a potential new treatment for Netherton Syndrome. Netherton Syndrome is a rare skin condition that can cause red, scaly skin and other symptoms. This particular study is testing a new medicine called DS-2325a.
The main goals of this study are to understand how safe DS-2325a is for people with Netherton Syndrome and how their bodies handle the medicine. Researchers will also be looking for any early signs that the medicine might improve the symptoms of Netherton Syndrome. This study uses a method where some people will get the active medicine, DS-2325a, and others will get a placebo. A placebo looks exactly like the medicine but contains no active ingredients. This is a common and important way to fairly compare the new medicine's effects.
Throughout the study, the research team will keep a close eye on participants. They'll check for any side effects, including serious ones, and monitor vital signs like temperature and blood pressure. They'll also review blood and urine tests and heart readings. To see if the medicine is working, they'll measure things like skin redness and scaling, and ask participants about their itching and how the condition affects their daily life. All of these checks help the researchers gather vital information about DS-2325a.
Points clés
- This study is testing a new medicine (DS-2325a) for Netherton Syndrome.
- It aims to check the medicine's safety and early signs of effectiveness.
- Participants will receive either the medicine or a placebo (dummy treatment).
- Close monitoring for side effects and symptom changes will happen throughout.
- It's for adults aged 18 and over, both men and women.
- You can withdraw from the study at any time without affecting your normal care.
Qui peut être éligible ?
To join this study, you need to be at least 18 years old. Both men and women are welcome to participate. Researchers are looking for people who have Netherton Syndrome.
There might be other specific health requirements or conditions that would qualify or disqualify someone from joining. For example, some existing health problems or medications might mean someone can't take part, as they could affect the safety of the new medicine or the accuracy of the study results.
If you're interested, it's really important to talk to the study doctors or your own doctor. They can give you all the details about what's needed to join and help you decide if it's right for you.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have Netherton Syndrome?
- Êtes-vous en mesure d'assister à des visites régulières à la clinique ?
- Are you comfortable with injections?
- Êtes-vous prêt à potentiellement recevoir un placebo ?
- Are you able to understand and agree to the study requirements?
En quoi consiste la participation ?
If you decide to take part in this study, you will be given either the new medicine, DS-2325a, or a placebo (a dummy medicine with no active ingredients). You won't know which one you're getting, and neither will the study team – this is called 'double-blind'. Both medicines will be given as injections.
Throughout the study, you'll have regular visits to the clinic. During these visits, the study team will carry out several assessments. This includes physical check-ups, taking your temperature, blood pressure, heart rate, and breathing rate. They will also take blood and urine samples for tests and perform an ECG (a heart tracing). In addition, they will carefully check your skin for any changes in redness or scaling, and you'll be asked about your symptoms, like itching, and how your condition affects your daily life by filling out questionnaires. Some participants might also be asked if they are willing to have small skin biopsies taken. The total length of your participation in the study, including the number of visits and follow-up, will be fully explained to you by the study team.
Risques et avantages potentiels
Emplacements (1)
- —Non vérifiéFrance
Questions fréquentes
What is Netherton Syndrome?
Netherton Syndrome is a rare genetic skin condition that causes red, scaly skin, especially from birth, and can also affect hair and cause other health issues.
Que signifie 'double aveugle' ?
Double-blind means neither you nor the doctors treating you will know if you are receiving the active medicine or the placebo. This helps ensure the study results are fair and unbiased.
Qu'est-ce qu'un placebo ?
A placebo is a substance that looks exactly like the study medicine but contains no active ingredients. It's used to compare against the real medicine.
Devrai-je payer pour participer à l'étude ?
No, you will not have to pay to participate in the study. All study-related care and medicines are provided free of charge.
Puis-je quitter l'étude si je change d'avis ?
Yes, you can choose to leave the study at any time, for any reason. Your decision will not affect your medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.